324 related articles for article (PubMed ID: 37950749)
1. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
[TBL] [Abstract][Full Text] [Related]
2. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
4. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract][Full Text] [Related]
5. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
6. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
7. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
Front Immunol; 2022; 13():887471. PubMed ID: 35935930
[TBL] [Abstract][Full Text] [Related]
8. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.
Bozorgi A; Bozorgi M; Khazaei M
Cell Oncol (Dordr); 2022 Oct; 45(5):755-777. PubMed ID: 35943716
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
12. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
13. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
15. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
16. Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer.
He Q; Hu H; Yang F; Song D; Zhang X; Dai X
Biomed Pharmacother; 2023 Jun; 162():114609. PubMed ID: 37001182
[TBL] [Abstract][Full Text] [Related]
17. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
18. CAR-NK cell in cancer immunotherapy; A promising frontier.
Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
[TBL] [Abstract][Full Text] [Related]
19. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
